Association between Eye Problems and GLP-1 Medications Such as Ozempic: Three Ocular Conditions Identified
New Study Details Link Between GLP-1 Meds and Eye Problems
Recent research has sparked interest in the potential side effects of using GLP-1 agonist medications for weight loss, such as Zepbound and Wegovy. A new study, published in the journal JAMA Ophthalmology, suggests a possible link between these drugs and the rare eye condition, nonarteritic anterior ischemic optic neuropathy (NAION).
Carrying on from this revelation, a recent investigatory review published in the journal PLOS One reported nine individuals who had been taking semaglutide and tirzepatide, the active ingredients in Zepbound and Mounjaro, respectively, experienced vision issues, including NAION, as well as two other potentially blinding conditions.
Unveiling the Connection
The study, led by Bradley Katz, MD, PhD, an ophthalmologist at the John A. Moran Eye Center and professor in the Department of Ophthalmology & Visual Sciences at the University of Utah, included nine participants with an average age of 58, five females, and four males. The research found seven of the study participants developed NAION, a potentially reversible condition if diagnosed early, while one participant experienced a retinal stroke, usually resulting in irreversible vision loss. The remaining individual did not lose vision but experienced swelling in both optic nerves.
While it is not yet clear what causes users of GLP-1 medications to experience these eye issues, the rapid fluctuations in blood sugar levels are suspected as a possible factor. Rapid changes in blood glucose levels may cause swelling in the optic nerve, which can lead to irreversible damage to vision in some cases. Katz and his team recommend consulting a healthcare provider for any sudden change in vision while using GLP-1 drugs and, for those starting or increasing the dose, do so slowly to minimize the risk of blood sugar drops and osmotic shifts.
Balancing Risk and Benefit
While the number of patients experiencing eye problems as a result of GLP-1 medication use is relatively low, it is essential for individuals to be aware of all potential side effects to make informed decisions about their health. Regular monitoring and reporting of any vision changes to healthcare providers are essential components of maintaining eye health while using these medications.
Medical professionals are advocating for a post-marketing survey to gain a more accurate understanding of the number of patients experiencing adverse ocular reactions from GLP-1 meds. Further research is needed to identify risk factors associated with eye problems in patients using these medications. As always, it is crucial to discuss any health concerns with healthcare providers to make informed decisions about your treatment options.
In light of the findings, individuals taking GLP-1 medications for weightloss, such as semaglutide and tirzepatide, should be vigilant about any vision changes. Rapid fluctuations in blood sugar levels, a suspected factor in these eye issues, underscore the importance of consulting healthcare providers for any sudden vision alterations and gradually increasing medication dosages.
